Viridian Therapeutics, Inc.
VRDN
$30.43
-$1.02-3.24%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 65.65% | -15.90% | -9.01% | -3.96% | -18.00% |
| Total Depreciation and Amortization | 439.82% | -3.42% | 408.70% | -97.53% | 554.93% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 3.43% | 17.34% | 35.31% | 16.22% | -33.66% |
| Change in Net Operating Assets | -480.26% | 214.51% | -3,111.96% | -84.50% | -73.33% |
| Cash from Operations | -12.26% | 18.65% | -26.35% | -8.31% | -47.00% |
| Capital Expenditure | -202.38% | 51.16% | 24.56% | 61.09% | -181.73% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 66.58% | -24.35% | 259.47% | 25.57% | -235.91% |
| Cash from Investing | 66.51% | -24.33% | 259.04% | 25.69% | -236.61% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 1,348.43% | -91.89% | -74.43% | -84.34% | 111,888.10% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -100.00% | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | 100.00% | 84.20% | 91.35% | -14,755.88% |
| Cash from Financing | 1,321.07% | -91.71% | -74.07% | -85.50% | 226,773.15% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 4,618.03% | -93.33% | 116.50% | -208.71% | 478.12% |